Vir's Phase 3 Success and Gilead Partnership Shift Thesis to Buy

What happened

Vir Biotechnology's Phase 3 ECLIPSE 1 trial for its Hepatitis Delta therapy met its primary endpoint with 44% efficacy and achieved 79% undetectable virus rates, alongside a clean safety profile with no discontinuations. This success, coupled with a newly announced major partnership with Gilead, materially de-risks the CHD program. Previously, our master report maintained a HOLD rating due to uncertainty around ECLIPSE outcomes and limited near-term catalysts. The company's cash position of $991.3 million translates to a $5.79 per share floor and extends funding runway into H2 2028. The positive trial results and partnership position Vir for potential first U.S. approval in HDV and strengthen its competitive standing.

Implication

The positive Phase 3 data and Gilead partnership substantially increase the probability of regulatory approval and commercial success for Vir's HDV therapy, justifying a more constructive stance. However, investors should recognize that much of this progress is now reflected in the stock price, limiting near-term upside. Key remaining risks include FDA approval, commercial execution, and the need for continued advancement of the oncology TCE pipeline to sustain long-term growth. The cash runway provides downside protection, but future value creation will depend on successful launch and additional pipeline milestones. Overall, the risk/reward has improved, but disciplined position sizing is advised given the balanced valuation.

Thesis delta

The prior HOLD thesis hinged on uncertainty around ECLIPSE 1 outcomes and lack of near-term catalysts. The positive Phase 3 results and the new Gilead partnership directly address these concerns, validating the CHD program and providing a clear path to commercialization. Consequently, we upgrade Vir to BUY, though we acknowledge that the stock's valuation now reflects much of this progress, limiting upside from current levels.